A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This study is testing a new antibody-drug conjugate called NN3201, which targets a protein called c-Kit found on certain cancer cells, in people with specific types of advanced cancers that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have an advanced or inoperable solid tumor such as gastrointestinal stromal tumor (GIST), small cell lung cancer, adenoid cystic carcinoma, uveal melanoma, neuroendocrine tumor, or a specific type of kidney cancer - Your cancer has progressed or is no longer responding to standard treatments, including imatinib for GIST - Your heart, liver, kidney, and bone marrow function are adequate - You have a life expectancy of at least 3 months - You are generally in good health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - Your prior cancer treatment has not been washed out long enough before starting this study - You are pregnant or of childbearing potential without using effective contraception Talk to your doctor to see if this trial is right for you.